Companies engaged in biotechnology, pharmaceuticals, research services, home healthcare, hospital operations, long‑term care, and the manufacture and supply of medical equipment and supplies. The sector also includes pharmaceutical retailers and providers of health‑information services. UK‑listed companies in this sector include AstraZeneca plc, GlaxoSmithKline plc, Smith & Nephew plc, Hikma Pharmaceuticals plc, ConvaTec Group plc, Spire Healthcare plc and EMIS Group plc.
AstraZeneca plc (LON:AZN) Alexion, AstraZeneca Rare Disease, has completed a definitive purchase and licence agreement for a portfolio of preclinical rare disease gene therapy programmes and enabling technologies from Pfizer..
GSK plc with ticker (LON:GSK) now has a potential upside of 13.1% according to Deutsche.Deutsche set a target price of 1,700 GBX for the company, which when compared to the..
AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 3.6% according to Deutsche.Deutsche set a target price of 11,000 GBX for the company, which when compared to the..
ConvaTec Group PLC with ticker (LON:CTEC) now has a potential upside of 35.4% according to RBC Capital Markets.RBC Capital Markets set a target price of 300 GBX for the company,..
AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 27.2% according to Barclays.Barclays set a target price of 13,500 GBX for the company, which when compared to the..
GSK plc (LON/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced that the European Commission has authorised Apretude (cabotegravir..
GSK plc (LON/NYSE: GSK) has announced that the Ministry of Health, Labour and Welfare (MHLW), Japan, has accepted for review a new drug application (NDA) for momelotinib, a potential new..
AstraZeneca plc with ticker (LON:AZN) now has a potential upside of 3.8% according to Deutsche.Deutsche set a target price of 11,000 GBX for the company, which when compared to the..
GSK plc with ticker (LON:GSK) now has a potential upside of 24.1% according to Deutsche.Deutsche set a target price of 1,700 GBX for the company, which when compared to the..
ConvaTec Group PLC with ticker (LON:CTEC) now has a potential upside of 33.3% according to Barclays.Barclays set a target price of 310 GBX for the company, which when compared to..
GSK plc (LON/NYSE:GSK) has announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has accepted for review a supplementary new drug application (sJNDA) for Nucala (mepolizumab), a monoclonal..
GSK plc (LON/NYSE: GSK) has announced positive results from the first-ever efficacy trial of Shingrix (Recombinant Zoster Vaccine or RZV) in China. These results come from the post-license phase IV..
Haleon plc (LON:HLN) has announced its 2023 half year results for the six months ended 30 June 2023 (unaudited). Strong growth, driven by price with another quarter of positive volume..
AstraZeneca plc (LON:AZN) Alexion has announced that it has entered a definitive purchase and licence agreement for a portfolio of preclinical gene therapy programmes and enabling technologies from Pfizer Inc...
GSK plc (LON/NYSE: GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, welcomed a positive opinion by the European..
AstraZeneca plc (LON:AZN) has announced datopotamab deruxtecan met dual primary endpoint of progression-free survival in patients with advanced non-small cell lung cancer in TROPION-Lung01 Phase III trial. Positive high-level results..
GSK plc (LON/NYSE:GSK) has announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved an updated indication for Shingrix (Recombinant Zoster Vaccine, Adjuvanted – RZV) for the..
GSK plc (LON/NYSE: GSK) today confirmed it has reached a confidential settlement with James Goetz, and the case he filed in California state court, set to begin trial on July..
GSK plc (LON/NYSE:GSK) has announced new data from the AReSVi-006 (Adult Respiratory Syncytial Virus) phase III trial evaluating the efficacy of a single dose of Arexvy (respiratory syncytial virus vaccine,..
The US Food and Drug Administration (FDA) Antimicrobial Drugs Advisory Committee (AMDAC) has voted unanimously 21 to 0 that AstraZeneca and Sanofi’s nirsevimab has a favourable benefit risk profile for..
